CHA
AUTL

Carmichael Hill & Associates’s Autolus Therapeutics AUTL Stock Holding History

Carmichael Hill & Associates’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-254
Closed -$1.62K – 781
2024
Q1 		$1.62K Sell
254
-254
-50% -$1.58K ﹤0.01% 694
2023
Q4 		$3.27K Hold
508
– – ﹤0.01% 678
2023
Q3 		$1.18K Hold
508
– – ﹤0.01% 723
2023
Q2 		$1.21K Hold
508
– – ﹤0.01% 729
2023
Q1 		$935 Hold
508
– – ﹤0.01% 732
2022
Q4 		$965 Hold
508
– – ﹤0.01% 727
2022
Q3 		$1K Hold
508
– – ﹤0.01% 761
2022
Q2 		$1K Hold
508
– – ﹤0.01% 747
2022
Q1 		$2K Hold
508
– – ﹤0.01% 739
2021
Q4 		$3K Buy
+508
New +$3.05K ﹤0.01% 736

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carmichael Hill & Associates's AUTL Position: Q2 2024 in Review

Carmichael Hill & Associates sold out of Autolus Therapeutics (AUTL) in Q2 2024, closing a stake of 254 shares — an estimated $1.62K sold.

Carmichael Hill & Associates first reported a position in AUTL in Q4 2021 and held it in 10 quarters. The position peaked at $3.27K in Q4 2023. 111 funds tracked by Wall St. Rank hold AUTL as of Q2 2024.

  • Carmichael Hill & Associates reported no remaining Autolus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Carmichael Hill & Associates sold 254 Autolus Therapeutics shares in Q2 2024, an estimated $1.62K.
  • Carmichael Hill & Associates first reported a position in Autolus Therapeutics in Q4 2021 and held it in 10 quarters.
  • Carmichael Hill & Associates's Autolus Therapeutics position peaked at $3.27K in Q4 2023.
  • 111 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2024.

Based on Carmichael Hill & Associates's 13F filing for Q2 2024, filed 2 Aug 2024.